Stock Scorecard
Stock Summary for Beam Therapeutics Inc (BEAM) - $25.01 as of 11/20/2024 7:48:54 PM EST
Total Score
12 out of 30
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for BEAM
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for BEAM
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for BEAM
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 | |
Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for BEAM
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Safety Rating Criteria for BEAM (39 out of 90)
Stock Price Rating (Max of 10) | 7 |
Historical Stock Price Rating (Max of 10) | 9 |
Stock Price Trend (Max of 10) | 1 |
Book Value (Max of 10) | 4 |
Book Value to Price (Max of 10) | 0 |
Analyst Buy Ratings (Max of 5) | 5 |
Analyst Strong Buy Ratings (Max of 5) | 4 |
Dividend Yield Percentage (Max of 10) | 0 |
Operating Margin (Max of 10) | 0 |
Trading Volume (Max of 10) | 9 |
Price to Earnings (Max of 10) | 0 |
Latest News for for BEAM
Financial Details for BEAM
Company Overview |
|
---|---|
Ticker | BEAM |
Company Name | Beam Therapeutics Inc |
Country | USA |
Description | Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. The company is headquartered in Cambridge, Massachusetts. |
Sector Name | LIFE SCIENCES |
Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
Most Recent Quarter | 9/30/2024 |
Next Earnings Date | N/A |
Stock Price History |
|
Last Day Price | 25.01 |
Price 4 Years Ago | 81.64 |
Last Day Price Updated | 11/20/2024 7:48:54 PM EST |
Last Day Volume | 1,154,027 |
Average Daily Volume | 1,192,373 |
52-Week High | 49.50 |
52-Week Low | 20.84 |
Last Price to 52 Week Low | 20.01% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 120.49 |
Sector PE | 40.32 |
5-Year Average PE | -12.83 |
Free Cash Flow Ratio | 2.24 |
Industry Free Cash Flow Ratio | 15.59 |
Sector Free Cash Flow Ratio | 27.97 |
Current Ratio Most Recent Quarter | 5.69 |
Total Cash Per Share | 11.18 |
Book Value Per Share Most Recent Quarter | 9.97 |
Price to Book Ratio | 2.65 |
Industry Price to Book Ratio | 5.50 |
Sector Price to Book Ratio | 20.88 |
Price to Sales Ratio Twelve Trailing Months | 5.99 |
Industry Price to Sales Ratio Twelve Trailing Months | 20.11 |
Sector Price to Sales Ratio Twelve Trailing Months | 7.11 |
Analyst Buy Ratings | 6 |
Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
Total Shares Outstanding | 82,806,000 |
Market Capitalization | 2,070,978,060 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Total Years Dividend Increasing | N/A |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | 54.16% |
Reported EPS 12 Trailing Months | -1.58 |
Reported EPS Past Year | -3.49 |
Reported EPS Prior Year | -1.90 |
Net Income Twelve Trailing Months | -143,591,000 |
Net Income Past Year | -132,527,000 |
Net Income Prior Year | -289,088,000 |
Quarterly Revenue Growth YOY | -17.00% |
5-Year Revenue Growth | 2,406.01% |
Operating Margin Twelve Trailing Months | -7.46 |
Balance Sheet |
|
Total Cash Most Recent Quarter | 925,800,000 |
Total Cash Past Year | 1,200,000,000 |
Total Cash Prior Year | 1,100,000,000 |
Net Cash Position Most Recent Quarter | 924,013,000 |
Net Cash Position Past Year | 1,196,993,000 |
Long Term Debt Past Year | 3,007,000 |
Long Term Debt Prior Year | 3,007,000 |
Total Debt Most Recent Quarter | 1,787,000 |
Equity to Debt Ratio Past Year | 1.00 |
Equity to Debt Ratio Most Recent Quarter | 1.00 |
Total Stockholder Equity Past Year | 981,329,000 |
Total Stockholder Equity Prior Year | 733,474,000 |
Total Stockholder Equity Most Recent Quarter | 791,317,000 |
Free Cash Flow |
|
Free Cash Flow Twelve Trailing Months | -145,373,000 |
Free Cash Flow Per Share Twelve Trailing Months | -1.76 |
Free Cash Flow Past Year | -182,927,000 |
Free Cash Flow Prior Year | -26,424,000 |
Options |
|
Put/Call Ratio | 0.07 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | 0.81 |
MACD Signal | 0.55 |
20-Day Bollinger Lower Band | 20.65 |
20-Day Bollinger Middle Band | 25.38 |
20-Day Bollinger Upper Band | 30.11 |
Beta | 1.86 |
RSI | 48.98 |
50-Day SMA | 26.60 |
150-Day SMA | 36.44 |
200-Day SMA | 50.01 |
System |
|
Modified | 11/20/2024 7:07:30 PM EST |